Arthneeti
MP

Mold-Tek Packaging Ltd

Q4 FY25Industrial Products

Mold-Tek Packaging Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹709
Market cap₹2.3K Cr
P/E30.3
Updated23 Aug 2026
Read4 min read

The short version

Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs.

From Mold-Tek Packaging Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. 30+ crores in FY26 and Rs. 50+ crores in FY27.
  • Pharma volumes aimed at 3,000 tons per annum by end of FY26, with revenue potential of Rs. 90-100 crores.
  • Paint segment growth in FY26 expected to reach double digits (~10%) driven by capacity expansions and increased IML adoption by Asian Paints.
  • Food & FMCG segment targeting 15%-20% growth in FY26 due to enhanced printing capacity and new client additions.
  • Overall company volume growth target for FY26 is around 15%.
  • EBITDA per kg expected to improve, with internal targets around Rs. 41-42 per kg in FY26, driven by pharma and food/FMCG segments.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Mold-Tek Packaging Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 CAPEX is guided between Rs. 70 to 80 crores, partly for pharma and printing expansion.
  • Pharma segment is getting Rs. 20-25 crores for land acquisition and building completion at Sultanpur.
  • Existing Sultanpur facility capacity being expanded from 1,500 tons to 3,000 tons per annum by March 2026.
  • New land (~2.5 acres) acquired adjacent to Sultanpur for future pharma expansion beyond 3,000 tons capacity.
  • Additional machines (injection molding, printing) being added; 5 new injection molding machines to arrive by June.
  • Printing capacity increased by 70% with investments of over Rs. 25 crores in the previous financial year.
  • ABG (Aditya Birla Group) capacity enhanced with Brownfield expansion, operating fully from March-April 2025.
  • Strategic focus on pharma growth: expecting 2.3x to 3x pharma revenue growth next financial year; exploring export opportunities.

2 more points management made on capital expenditure plans

Top-ranked in Industrial Products

Ranked on what management guided this quarter

5x potential
1Susan Electrical
Rev 1Mar 1
2Shera Energy
Rev 1Mar 1
3
Rev 1Mar 1
4
Rev 1Mar 2
5
Rev 1Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Mold-Tek Packaging Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from the Mold-Tek Packaging Limited conference call on May 19, 2025, does not explicitly mention details about the current or expected order book or pending orders. However, some relevant insights include: - The Pharma division showed strong growth, with a 3x turnover increase in Q4 and a base established for future quarters, indicating a healthy order inflow. - Capacity utilization improvements at ABG and various plants (e.g., Satara running at 75%-80% capacity in April) suggest increasing order volumes. - Asian Paints has progressively shifted brands into IML, enhancing order volumes for Mold-Tek across multiple plants.

2 more points management made on order book & pipeline

Mold-Tek Packaging Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Mold-Tek Packaging Ltd's management said in earlier quarters

Others in Industrial Products this season

  • Graphite India Ltd (Q4 FY25)

    666 Crores, down 7.5% year-on-year (YoY) from Rs. Key concall takeaways from Graphite India Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Welspun Specialty Solutions Ltd (Q4 FY25)

    Q4 FY25 Revenue: INR 2,085 million, up 33% YoY from INR 1,564 million in Q4 FY24 (Page 12, Page 11) . Key concall takeaways from Welspun Specialty Solutions…

  • Grindwell Norton Ltd (Q4 FY25)

    Revenue from Operations for FY 2024-25 is ₹2812 crores, a 4.6% increase from ₹2687 crores in FY 2023-24. Key concall takeaways from Grindwell Norton Ltd's Q4…

  • PTC Industries Ltd (Q4 FY25)

    Q4 FY25 Total Income:** ₹133.8 Cr, up 74.9% YoY from ₹76.5 Cr in Q4 FY24 (Page 6, 5). Key concall takeaways from PTC Industries Ltd's Q4 FY25 earnings call…

Compare:vs Polycab India Ltdvs Welspun Corp Ltdvs APL Apollo Tubes

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Mold-Tek Packaging Ltd Q4 FY25 results?

Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs.

What is Mold-Tek Packaging Ltd share price analysis?

Mold-Tek Packaging Ltd currently shows a neutral. The stock trades at a P/E of 30.3 with a market cap of ₹2,307 Cr. Investors should review the full earnings analysis for detailed insights.

Is Mold-Tek Packaging Ltd planning capital expenditure?

FY '26 CAPEX is guided between Rs.

Keep Mold-Tek Packaging Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.